Dr. Vosganian is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10666 N Torrey Pines Rd
MS 312
La Jolla, CA 92037Phone+1 858-554-8116
Education & Training
Scripps Clinic/Scripps Green HospitalFellowship, Hematology and Medical Oncology, 2008 - 2011
University of California Davis HealthResidency, Internal Medicine, 2005 - 2008
Virginia Commonwealth University School of MedicineClass of 2005
Certifications & Licensure
CA State Medical License 2006 - 2026- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 8 citationsFirst-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.Antoine Italiano, Philippe A. Cassier, Chia-Chi Lin, Tuomo Alanko, K. Peltola
Cancer Immunology, Immunotherapy. 2021-07-03 - 9 citationsSafety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer.Emiliano Calvo, Alexander I. Spira, Maria de Miguel, Shunsuke Kondo, Anas Gazzah
Cancer Treatment and Research Communications. 2021-01-01 - 5 citationsModel Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).John D. Powderly, Alexander I. Spira, Shunsuke Kondo, Toshihiko Doi, Jason J. Luke
Clinical and Translational Science. 2021-01-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
